During the past decade, Pittsburgh CRS (1001) conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 10 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pittsburgh CRS (1001)" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 16 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "Exegi Pharma, LLC" with 1 trials as a collaborator, "National Institute on Aging (NIA)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Pittsburgh CRS (1001)" are "HIV-1 Infection" (9 trials), "HIV Infections" (5 trials), "HIV Infection" (1 trials), "HIV-1-infection" (1 trials) and "Hepatitis C" (1 trials). Many other conditions were trialed in "Pittsburgh CRS (1001)" in a lesser frequency.

Most popular intervention types in "Pittsburgh CRS (1001)" are "Drug" (16 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abacavir/Lamivudine" (1 trials), "Abacavir/Lamivudine placebo" (1 trials), "Antiretroviral treatment pause" (1 trials) and "Atazanavir" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pittsburgh CRS (1001)" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Pittsburgh CRS (1001)". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Pittsburgh CRS (1001), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pittsburgh CRS (1001), 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".